BeiGene trial investigator Jennifer Brown of Dana-Farber Cancer Institute presents the ALPINE results at ASH on Dec. 13 in New Orleans (Photo: Assistant editor Paul Schloesser for Endpoints News)

December 13, 2022 10:00 AM ESTUpdated 01:06 PM

#ASH22: BeiGene's BTK inhibitor shows superiority to AbbVie, J&J blockbuster in PFS

Paul Schloesser

Associate Editor

Kyle LaHucik

Senior Reporter

NEW ORLEANS — As the last six abstracts were presented at the American Society of Hematology on Tuesday, BeiGene sought to establish that its BTK inhibitor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASH22: BeiGene's BTK inhibitor shows superiority to AbbVie, J&J blockbuster in PFS

Paul Schloesser

Associate Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Sofinnova outlines $550M fund after IPOs and M&A deals

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

#ASH22: BeiGene's BTK in­hibitor shows su­pe­ri­or­i­ty to Ab­b­Vie, J&J block­buster in PFS

Associate Editor

Senior Reporter

Sign up to read this article for free.

more like this

#ASH22: BeiGene's BTK inhibitor shows superiority to AbbVie, J&J blockbuster in PFS